¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

2024³â Á¦2ȸ ´ëÇѼҾƺñ´¢ÀÇÇÐȸ Transitional Urology Symposium : 2024-06-29

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 

2024³â Á¦2ȸ ´ëÇѼҾƺñ´¢ÀÇÇÐȸ Transitional Urology Symposium : 2024-06-29
±³À°ÀÏÀÚ : 2024-06-29
±³À°Àå¼Ò : ºÎ»ê ¾Æ½ºÆ¼È£ÅÚ 22Ãþ ±×·£µåº¼·ë

±³À°ÁÖÁ¦ : 2024³â Á¦2ȸ ´ëÇѼҾƺñ´¢ÀÇÇÐȸ Transitional Urology Symposium

ÁÖÃÖ±â°ü : ´ëÇѺñ´¢ÀÇÇÐȸ(19.2 ¸íĪº¯°æ ´ëÇѺñ´¢±â°úÇÐȸ)
½ÃÇà±â°ü(ÁöºÎ/°ú) : ´ëÇѼҾƺñ´¢ÀÇÇÐȸ

´ã´çÀÚ : À̼¼Èñ
¿¬¶ôó : 02-573-8190

À̸ÞÀÏ : urology@urology.or.kr

±³À°Á¾·ù : ºñ´¢ÀÇÇаú

Âü¼®¿¹»óÀÎ : 50¸í
Èñ¸ÁÆòÁ¡ : 2Á¡

Áö¿ª : ºÎ»ê±¤¿ª½Ã
±³À°½Ã°£ : 3 ½Ã°£ 10ºÐ

¼¼ºÎ¼ö°­·á : 22,000¿ø  

ºñ°í ȸºñ ³³ºÎ¿¡ µû¶ó Â÷µî ºÎ°úÇÒ ¼ö ÀÖÀ½


±¸ºÐ ¿ùÀÏ °­ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ

±³À°½Ã°£ 06¿ù 29ÀÏ ºÎ»ê ¾Æ½ºÆ¼È£ÅÚ 22Ãþ ±×·£µåº¼·ë 09:00~09:30 Enuresis and nocturia in an adolescence ±è¼ºÃ¶, °íÇõÁØ(¿ï»êÀÇ´ë, µ¿¾ÆÀÇ´ë)

±³À°½Ã°£ 06¿ù 29ÀÏ ºÎ»ê ¾Æ½ºÆ¼È£ÅÚ 22Ãþ ±×·£µåº¼·ë 09:30~10:00 Overactive bladder and urinary incontinence symptoms in an adolescence ÀÓ¿µÀç, ±èµ¿¼ö(¼­¿ïÀÇ´ë, °æÈñÀÇ´ë)

Åä·Ð 06¿ù 29ÀÏ ºÎ»ê ¾Æ½ºÆ¼È£ÅÚ 22Ãþ ±×·£µåº¼·ë 10:00~10:30 Panel discussion ()

ÈÞ½Ä 06¿ù 29ÀÏ ºÎ»ê ¾Æ½ºÆ¼È£ÅÚ 22Ãþ ±×·£µåº¼·ë 10:30~10:50 Break ()

±³À°½Ã°£ 06¿ù 29ÀÏ ºÎ»ê ¾Æ½ºÆ¼È£ÅÚ 22Ãþ ±×·£µåº¼·ë 10:50~11:10 Management of ureterocele ÇÏÁö¿ë(°è¸íÀÇ´ë)

±³À°½Ã°£ 06¿ù 29ÀÏ ºÎ»ê ¾Æ½ºÆ¼È£ÅÚ 22Ãþ ±×·£µåº¼·ë 11:10~11:30 Management of ureteropelvic junction obstruction (UPJO) ¹èÀçÇö(°í·ÁÀÇ´ë)

Åä·Ð 06¿ù 29ÀÏ ºÎ»ê ¾Æ½ºÆ¼È£ÅÚ 22Ãþ ±×·£µåº¼·ë 11:30~12:00 Panel discussion ()

±³À°½Ã°£ 06¿ù 29ÀÏ ºÎ»ê ¾Æ½ºÆ¼È£ÅÚ 22Ãþ ±×·£µåº¼·ë 12:00~12:15 Clinical Utility of Low-dose ¥â3-Adrenoreceptor Agonists, Mirabegron, for the Treatment of Overactive Bladder : In children(KSPU) ¼Û»óÈÆ(¿ï»êÀÇ´ë)

±³À°½Ã°£ 06¿ù 29ÀÏ ºÎ»ê ¾Æ½ºÆ¼È£ÅÚ 22Ãþ ±×·£µåº¼·ë 12:15~12:30 Clinical Utility of Low-dose ¥â3-Adrenoreceptor Agonists, Mirabegron, for the Treatment of Overactive Bladder : In adult(KCS) ¹èÈ£¿µ(¿ï»êÀÇ´ë)

 

ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" 2024³â Á¦2ȸ ´ëÇѼҾƺñ´¢ÀÇÇÐȸ Transitional Urology Symposium : 2024-06-29""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û Á¦12ȸ ÀÎÁ¦ÀÇ´ë ÀÏ»ê¹éº´¿ø ½Å°æ¿Ü°ú ¿¬¼ö°­Á : 2024-06-29
´ÙÀ½±Û 2024³â ´ëÇѳëÀνŰæÀÇÇÐȸ Ãá°èÇмú´ëȸ : 2024-06-29
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20762 ¼­¿ï (¿Â¶óÀÎ) ´ëÇѼҾÆÀÀ±ÞÀÇÇÐȸ Á¦ 32ȸ Á¤±â Áý´ãȸ : 2024-06-10 0 103 2024-05-27
20761 ¼­¿ï °í·Á´ëÇб³±¸·Îº´¿ø Á¦16ȸ KOALA Symposium 2024 : 2024-06-09 0 104 2024-05-27
20760 ¼­¿ï 2024³âµµ ¼¼ºê¶õ½ºº´¿ø IBD¼ÒÈ­±â³»°ú ¿¬¼ö°­Á : 2024-06-09 0 76 2024-05-27
20759 ºÎ»ê 2024³â ¿µ³² ½ÉÃÊÀ½ÆÄ ¿¬¼ö°­Á : 2024-06-09 0 32 2024-05-27
20758 ¼­¿ï 2024 ´ëÇÑÆòÇüÀÇÇÐȸ Á¦46Â÷ Ãá°èÇмú´ëȸ ¹× Á¦13Â÷ ±³À°°­Á : 2024-06-09 0 32 2024-05-27
20757 ¼­¿ï ´ëÇÑ°üÀý°æÇÐȸ – Á¦11ȸ °üÀý°æ ¼ö¼ú ½ÉÆ÷Áö¾ö : 2024-06-09 0 79 2024-05-27
20756 ¼­¿ï ´ëÇѽŰæÁ¤½ÅÀÇÇÐȸ Çѱ¹ÀÓ»ó¿¹¼úÇÐȸ ÇÏ°èÇмú´ëȸ ¹× ¿öÅ©¼ó : 2024-06-09 0 36 2024-05-27
20755 ¼­¿ï ´ëÇÑÇǺοܰúÇÐȸ KSDS 2nd International Congress SEOUL 2024 (2ÀÏÂ÷) : 2024-06-09 0 49 2024-05-27
20754 ºÎ»ê ´ëÇѺñ´¢ÀÇÇÐȸ Á¦88ȸ ºÎ»êºñ´¢ÀÇÇÐÆ÷·³ : 2024-06-08 0 54 2024-05-27
20753 ¼­¿ï 2024 Á¤½Å½ÅüÀÇÇÐ Àü¹®°¡°úÁ¤ º¸¼ö±³À° : 2024-06-08 0 44 2024-05-27
20752 °æ±â ÀÇÁ¤ºÎÀ»Áö´ëÇб³º´¿ø Àü±â°æ·ÃÄ¡·áÀÇ ÃÖ½ÅÁö°ß°ú ÀÓ»óÀû¿ë : 2024-06-08 0 53 2024-05-27
20751 °æ±â 2024 Á¦4ȸ ¿¬¼¼ÀÇ´ë ÀÔ¿øÀÇÇаú ½ÉÆ÷Áö¾ö : 2024-06-08 0 84 2024-05-27
20750 ¼­¿ï (¿Â¶óÀÎ) Á¦74Â÷ ´ëÇѼҾÆû¼Ò³â°úÇÐȸ Ãá°èÇмú´ëȸ : 2024-06-08 0 46 2024-05-27
20749 ¼­¿ï 2024 ¼ö¸éÈ£ÈíÀå¾Ö ¿¬±¸È¸ & ÁýÁßÄ¡·á ¿¬±¸È¸ °øµ¿½ÉÆ÷Áö¾ö : 2024-06-08 0 56 2024-05-27
20748 ¼­¿ï 2024 Á¦32Â÷ ´ëÇѼҾƸ¶ÃëÇÐȸ Çмú´ëȸ : 2024-06-08 0 54 2024-05-27
31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷